Abstract
In The Lancet HIV, Anna Turkova and colleagues1 report the findings of a pharmacokinetic and safety substudy nested within the ODYSSEY trial, which provides evidence that twice-daily dolutegravir dosing is safe and effective when used with rifampicin-containing tuberculosis (TB) treatment in children with HIV-associated TB. Their findings support the 2021 WHO HIV recommendations for once-daily dolutegravir as a component of first-line and second-line HIV treatment from age 4 weeks or older, and twice-daily dosing during treatment with rifampicin-based therapy for TB coinfection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
